close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.63 -0.33 (-1.52%)
Streaming Delayed Price Updated: 2:34 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta and Petco and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
FDA Official Who Halted Sarepta’s Gene Therapy Resigns Amid Backlash Over Access To Duchenne Treatment
Via Stocktwits
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi &amp; Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Trump Overrode RFK Jr. And Makary To Remove FDA Biologics Chief Amid Sarepta Drug Controversy: Report
The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics. 
Via Stocktwits
Topics Death ETFs Government
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
REPL Stock Nearly Doubled In Value Today: What's Going On?
Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 
Via Stocktwits
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
Investors Who Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Investors Who Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi &amp; Korsinsky About Pending Class Action - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Dow Futures Edge Up Ahead Of Fed Meeting, Big Tech Earnings: MSFT, META, F, HOOD, SRPT, SOFI Among Stocks To Watch
While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures rose 0.1%. 
Via Stocktwits
Topics ETFs Economy Government
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi &amp; Korsinsky About Pending Class Action - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys
JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. 
Via Stocktwits
Topics Death
FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers
Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development. 
Via Benzinga
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views
 
Via Benzinga
Topics Earnings
Top movers analysis in the middle of the day on 2025-07-29: top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments
Sarepta stock soared after the FDA said the biotech company can resume shipments of a controversial gene therapy drug. 
Via Investor's Business Daily
Topics Workforce
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today